Literature DB >> 22351693

A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.

Xavier M Keutgen1, Filippo Filicori, Michael J Crowley, Yongchun Wang, Theresa Scognamiglio, Rana Hoda, Daniel Buitrago, David Cooper, Martha A Zeiger, Rasa Zarnegar, Olivier Elemento, Thomas J Fahey.   

Abstract

PURPOSE: Indeterminate thyroid lesions on fine needle aspiration (FNA) harbor malignancy in about 25% of cases. Hemi- or total thyroidectomy has, therefore, been routinely advocated for definitive diagnosis. In this study, we analyzed miRNA expression in indeterminate FNA samples and determined its prognostic effects on final pathologic diagnosis. EXPERIMENTAL
DESIGN: A predictive model was derived using 29 ex vivo indeterminate thyroid lesions on FNA to differentiate malignant from benign tumors at a tertiary referral center and validated on an independent set of 72 prospectively collected in vivo FNA samples. Expression levels of miR-222, miR-328, miR-197, miR-21, miR-181a, and miR-146b were determined using reverse transcriptase PCR. A statistical model was developed using the support vector machine (SVM) approach.
RESULTS: A SVM model with four miRNAs (miR-222, miR-328, miR-197, and miR-21) was initially estimated to have 86% predictive accuracy using cross-validation. When applied to the 72 independent in vivo validation samples, performance was actually better than predicted with a sensitivity of 100% and specificity of 86%, for a predictive accuracy of 90% in differentiating malignant from benign indeterminate lesions. When Hurthle cell lesions were excluded, overall accuracy improved to 97% with 100% sensitivity and 95% specificity.
CONCLUSIONS: This study shows that that the expression of miR-222, miR-328, miR-197, and miR-21 combined in a predictive model is accurate at differentiating malignant from benign indeterminate thyroid lesions on FNA. These findings suggest that FNA miRNA analysis could be a useful adjunct in the management algorithm of patients with thyroid nodules. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351693     DOI: 10.1158/1078-0432.CCR-11-2487

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  57 in total

Review 1.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

Review 2.  Current methodologies for molecular screening of thyroid nodules.

Authors:  Elisabetta Macerola; Fulvio Basolo
Journal:  Gland Surg       Date:  2018-08

3.  Cancer: Indeterminate thyroid nodules--added testing, added value?

Authors:  Jin Young Kwak; Eun-Kyung Kim
Journal:  Nat Rev Endocrinol       Date:  2013-04-16       Impact factor: 43.330

Review 4.  Diagnostic biomarkers of differentiated thyroid cancer.

Authors:  Tada Kunavisarut
Journal:  Endocrine       Date:  2013-05-04       Impact factor: 3.633

Review 5.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

6.  Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples.

Authors:  Yang Zhang; Qi Zhong; Xiaohong Chen; Jugao Fang; Zhigang Huang
Journal:  Tumour Biol       Date:  2014-06-19

7.  MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.

Authors:  Matthias S Dettmer; Aurel Perren; Holger Moch; Paul Komminoth; Yuri E Nikiforov; Marina N Nikiforova
Journal:  J Mol Endocrinol       Date:  2014-03-06       Impact factor: 5.098

Review 8.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

9.  The sensitivity and specificity of thyroglobulin concentration using repeated measures of urinary iodine excretion.

Authors:  Zheng F Ma; Bernard J Venn; Patrick J Manning; Claire M Cameron; Sheila A Skeaff
Journal:  Eur J Nutr       Date:  2017-03-11       Impact factor: 5.614

10.  Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis.

Authors:  Zhihong Wang; Hao Zhang; Ping Zhang; Jing Li; Zhongyan Shan; Weiping Teng
Journal:  Med Oncol       Date:  2013-04-23       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.